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Lafora disease (LD) is an autosomal recessive, progressive myoclonus epilepsy, which is characterized by
the accumulation of polyglucosan inclusion bodies, called Lafora bodies, in the cytoplasm of cells in the cen-
tral nervous system and in many other organs. However, it is unclear at the moment whether Lafora bodies
are the cause of the disease, or whether they are secondary consequences of a primary metabolic alteration.
Here we describe that the major genetic lesion that causes LD, loss-of-function of the protein laforin, impairs
autophagy. This phenomenon is conﬁrmed in cell lines from human patients, mouse embryonic ﬁbroblasts
from laforin knockout mice and in tissues from such mice. Conversely, laforin expression stimulates auto-
phagy. Laforin regulates autophagy via the mammalian target of rapamycin kinase-dependent pathway.
The changes in autophagy mediated by laforin regulate the accumulation of diverse autophagy substrates
and would be predicted to impact on the Lafora body accumulation and the cell stress seen in this disease
that may eventually contribute to cell death.
INTRODUCTION
Lafora disease (LD) is an autosomal recessive, progressive
myoclonus epilepsy that manifests during adolescence with
generalized tonic–clonic seizures, myoclonus, absences,
drop attacks and visual hallucinations. The disease results in
progressive neurodegeneration, and death follows about 10
years after onset (1,2). The pathological hallmark of LD is
the accumulation of polyglucosan inclusion bodies, called
Lafora bodies, in the cytoplasm of cells in many organs.
Lafora bodies contain around 90% of a poorly branched
form of glycogen resembling amylopectin and 6% protein
(3) and are also decorated by anti-ubiquitin antibodies (4,5).
The extent of Lafora body deposition correlates with neuronal
cell death and seizure frequency. Thus, it has been suggested
that Lafora bodies may cause the pathology (6), but this has
not yet been ﬁrmly established.
Thegreatmajority(90%)ofmutationscausingLDhavebeen
identiﬁed in two genes: EPM2A, which encodes laforin, a
member of the dual-speciﬁcity protein phosphatase family,
and EPM2B, which codes for malin, a protein with an NH2-
terminal RING ﬁnger domain characteristic of an important
group of E3-ubiquitin ligases (7–9). There is also evidence
for a third minor locus (10). Patients carrying homozygous
loss-of-function mutations in laforin or malin are indistinguish-
able suggesting that both proteins work together in the same
†Present address: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge, MA 02142,
USA.
‡The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
}Joint senior authors.
∗To whom correspondence should be addressed. Tel: +44 1223762608; Fax: +44 1223331206; Email: dcr1000@hermes.cam.ac.uk
# The Author 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop-
erly cited.
Human Molecular Genetics, 2010, Vol. 19, No. 14 2867–2876
doi:10.1093/hmg/ddq190
Advance Access published on May 7, 2010physiological pathway. However, it is unclear how laforin and
malin loss-of-function are related with the disease. Laforin
interacts physically with malin and the complex causes speciﬁc
ubiquitination and proteasome-dependent degradation of pro-
teins involved in the regulation of glycogen biosynthesis
(11–15). In addition, laforin acts as a glycogen phosphatase,
and it appears that it can suppress excessive glycogen phos-
phorylation, thereby preventing the formation of the phos-
phorylated, poorly branched and aggregate-prone glycogen
polymers that comprise Lafora bodies (16–19). While LD
could be an error of carbohydrate metabolism, it has also
been proposed to be a disorder of protein clearance (20).
Here we have considered the possibility that a deﬁciency in
autophagy may be a feature of LD, and that it may contribute
to the accumulation of Lafora bodies. Macroautophagy (which
we will henceforth call autophagy) is a process that cells use
to degrade intracytoplasmic proteins, protein complexes/oligo-
mers, organelles and certain intracellular pathogens (21–24). It
is initiated when cells form a double-layered vesicle, an autop-
hagosome,aroundaportionofcytoplasm.Autophagosomesare
trafﬁcked to lysosomes where they ultimately fuse, allowing
their contents to be degraded by the lysosomal hydrolases. We
tested if autophagy was affected by the laforin mutation for
three main reasons. First, autophagy is a crucial route for the
removal of disease-associated, intracytoplasmic, aggregate-
prone proteins, since it can engulf oligomeric and larger struc-
tures that cannot enter the narrow channel of the proteasome
barrel(21–24).Whenautophagyisinhibited,thentheclearance
of such proteins is retarded, leading to increased aggregate for-
mation. Second, when autophagy is inhibited in otherwise
normal mice, then proteins accumulate in inclusions that are
decorated by anti-ubiquitin antibodies (25). Third, autophagy
is an important route for intracellular glycogen degradation
(26,27). Our data in patient cells, laforin knockout mice and in
cell culture systems show that laforin is a positive regulator of
autophagy, via mammalian target of rapamycin kinase
(mTOR), and therefore suggest that autophagy compromise
may contribute to the pathology seen in LD.
RESULTS
Lack of laforin inhibits autophagosome formation
To assess macroautophagic activity, we ﬁrst used the classical
autophagosome marker LC3. During the formation of autopha-
gicvacuoles,thecytoplasmicLC3-Iisoformisconvertedbylipi-
dation into LC3-II that has increased mobility in SDS–PAGE.
LC3-II is the only known protein that associates speciﬁcally
with autophagosomes and not with other organelles and is
degraded in an autophagy-dependent fashion in lysosomes.
Therefore, the levels of LC3-II (relative to actin or tubulin) cor-
relate with the numbers of autophagosomes in the cells. The
number of autophagosomes can be altered due to either
changes in synthesis or in degradation. If one clamps LC3-II/
autophagosome degradation by treating cells with lysosomal
inhibitors (28), then changes in the levels of LC3-II will reﬂect
alterations in the rate of LC3-II/autophagosome formation.
To further assess autophagic responses in our experiments,
we have cultured cells in serum- and amino acid-free medium
(Krebs–Henseleit medium) to stimulate autophagy via the
well-described starvation response (H, for high proteolysis),
or in full medium to assess basal autophagy (L, for low proteo-
lysis). Human ﬁbroblasts from LD patients lacking laforin
(Supplementary Material, Fig. S1) had lower levels of LC3-II
in the presence and absence of the lysosomal inhibitor baﬁlo-
mycin A1, compared with control cells (Fig. 1A–C, and see
also Supplementary Material, Fig. S2 for comparison with
other control ﬁbroblasts). Likewise, mouse embryonic ﬁbro-
blasts (MEFs) from laforin null mice (Epm2a
2/2, Supplemen-
tary Material, Fig. S1) had lower levels of LC3-II in the
presence and absence of the lysosomal inhibitor baﬁlomycin
A1, compared with control cells, in both full medium and star-
vation conditions (Fig. 1D–F). Thus, a lack of laforin impairs
autophagosome synthesis both in human patient ﬁbroblasts
and in MEFs. This is consistent with a reduction in the
numbers of autophagic vesicles in the LD patient cell lines
(Laf-),asassessedbyEGFP-LC3vesiclenumbers(Supplemen-
tary Material, Fig. S3). Note that LC3-I levels vary between
differentcelltypes,asdoesLC3-IIinductioninresponsetostar-
vation. There may be some clonal variability in different cell
lines, and that is why we have tested different control and
patient human cells lines as well as MEFs. In all cases, we
observedareduction inautophagy inthe laforin-defective cells.
Long-lived protein degradation is impaired in LD cells
Under basal conditions, autophagy only degrades a very small
proportion of long-lived proteins. However, when cells are
starved and autophagy is induced, then this process contributes
to a substantial proportion of long-lived protein degradation.
Consistent with our LC3 data above, long-lived protein degra-
dation was impaired in LD cell lines, compared with normal
ﬁbroblasts, and also in MEFs from laforin null mice, compared
with control wild-type MEFs (Fig. 2A and B). This was
associated with a defect in autophagic protein degradation,
which one can assess by measuring the amount of long-lived
protein degradation that is sensitive to the autophagy inhibitor
3-methyladenine. When autophagy is impaired, there is an
increase in ubiquitinated proteins (25). Conversely, the
levels of ubiquitinated proteins are decreased in normal cells
under starvation/high autophagy conditions. Levels of ubiqui-
tinated proteins were elevated in LD ﬁbroblasts, compared
with control cells (Fig. 2C and D and Supplementary Material,
Fig. S4A and B), and in laforin null MEFs, compared with
control MEFs (Supplementary Material, Fig. S5), in both star-
vation and full media. These differences in the levels of ubi-
quitinated proteins were still present in cells treated with the
proteasome inhibitor MG132 (Fig. 2D and Supplementary
Material, Figs S4B and S5B and D), compatible with the
observed differences among laforin and wild-type cells being
proteasome-independent and likely due to autophagy.
Autophagy is impaired in laforin knock-out mice
In order to test whether laforin regulates autophagy in vivo,w e
have studied laforin knockout mice (Epm2a
2/2, Supplemen-
tary Material, Fig. S1). In these mice, we can assay auto-
phagosome number in the liver and relate this to synthesis
by measuring LC3-II in the presence or absence of the lysoso-
mal inhibitor leupeptin. Leupeptin is a cysteine protease
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endocytosis and inhibits important lysosomal cathepsins.
Therefore, it can be used as an equivalent to baﬁlomycin A1
in this context, but we have used leupeptin for the in vivo
studies as it may have less organismal toxicity. Consistent
with our data in the patient cell lines, liver extracts from
laforin knockout mice have decreased numbers of autophago-
somes that can be attributed to impaired autophagosome syn-
thesis. This is apparent both in mice of 3 and 12 months of age
(Fig. 3A and B).
To conﬁrm the observed autophagy impairment, we also
assayed the levels of the endogenous autophagy substrate
p62, which was increased in laforin-null mice (Fig. 3C and
D). Likewise, the levels of ubiquitinated proteins were
increased in both fed and starved laforin null mice compared
with wild-type controls (Fig. 3E and F and Supplementary
Material, Fig. S4C and D). While small differences were
seen at 1 month of age and in 12 h starved mice at 3 months
of age, these differences became very clear in 3-month-old
mice starved for 24 h.
The mTOR pathway is upregulated by laforin deﬁciency
The mTOR is a major negative regulator of autophagy (29).
mTOR can be inhibited, leading to autophagy induction, by
starvation (30). Indeed, starvation of both control ﬁbroblasts
and wild-type mice leads to decreased phosphorylation (at
the mTOR site) of the mTOR substrate p70S6 kinase (a con-
ventional readout for mTOR kinase activity) (Fig. 4).
Laforin deﬁciency in human ﬁbroblasts (Fig. 4A) and in
vivo (Fig. 4B) correlated with a marker of increased mTOR
activity. This suggested that the autophagy defect in laforin
null cells may be mTOR-dependent.
Laforin overexpression induces autophagy
We also assessed whether laforin overexpression could induce
autophagosome formation. Consistent with the laforin null
data above, overexpression of laforin increased the levels of
LC3-II in the presence of baﬁlomycin A1, suggesting an
increase in autophagosome synthesis in both COS-7 and
SK-N-SH (neuroblastoma) cell lines (Fig. 5A). Furthermore,
laforin overexpression increased EGFP-LC3 vesicle numbers
(Fig. 5B).
One way of assessing autophagic substrate clearance is to
examine if a perturbation changes the percentage of cells
with aggregates after expression of exogenous EGFP-
HDQ74, an enhanced green ﬂuorescent protein-tagged
version of mutant huntingtin exon 1 with 74 polyglutamine
(polyQ) repeats. Mutant huntingtin exon 1, which is associated
with Huntington’s disease, is an excellent autophagy substrate,
and its levels and the percentage of cells with aggregates
Figure 1. Loss of laforin decreases formation of autophagosomes. (A, B, D, E) Representative immunoblots, using antibodies which recognize LC3 or, as a
loading control, actin, with extracts (75 mg protein) of human ﬁbroblasts from a control individual (CTR-1) and from two different LD patients (Laf-1 and
Laf-2) (A and B), or of MEFs from control (Epm2a
+/+) and laforin-deﬁcient (Epm2a
2/2) mice (D and E), incubated for 2 h without (A and D) and with
(B and E) baﬁlomycin A1 (400 nM) under conditions of high (H, Krebs-Henseleit medium) and low (L, full medium) proteolysis. The positions of LC3-I
and LC3-II bands are indicated on the left. (C and F) The LC3-II bands from three independent experiments similar to those shown in (B) and (E), respectively,
were quantiﬁed by densitometry and normalized to the corresponding actin bands. Data are expressed in percent relative to control cells.
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tage of cells with aggregates is reduced when autophagy is
induced (31). Laforin overexpression reduced the percentage
of cells with mutant huntingtin aggregates, which was also
associated with lower cell death (Fig. 5C). This was
autophagy-dependent, as laforin only had these effects in
autophagy-competent MEFs (atg5
+/+), but not in Atg5 null,
autophagy-incompetent cells (atg5
2/2) (Fig. 5D).
Laforin induces autophagy via the mTOR pathway
Consistentwiththelaforinknockoutdataabove,laforinoverex-
pression decreased mTOR activity, as assessed by phosphoryl-
ation of p70S6K (and the levels of phosphorylation of its
substrate S6P) (Fig. 6A). To test whether laforin-mediated
autophagy was mTOR-dependent, we tested its effects in cells
where mTOR was constitutively activated due to loss of its
upstream inhibitor TSC2 (32). While laforin overexpression
together with mutant huntingtin exon 1 increased autophago-
some numbers (Fig. 6B) and decreased the percentages of
cells with polyQ aggregates (Fig. 6C) in wild-type MEFs
(tsc2
+/+), the mitigating effects of laforin overexpression
werenotseeninTSC2nullMEFs(tsc2
2/2),which,asexpected,
had fewer autophagosomes and more aggregates due to
impaired autophagy. These data suggest that laforin modulates
autophagy either at the level of TSC2 or above this protein.
DISCUSSION
Our data show that a lack of laforin decreases autophagy. This
was assessed using a range of assays. In patient cells, MEFs
and mice, we observed decreased autophagosome formation
Figure 2. Loss of laforin decreases the degradation of long-lived proteins by macroautophagy and increases accumulation of polyubiquitinated proteins. (A and
B) Intracellular protein degradation (total) and the amount of protein degraded by macroautophagy (MA) was calculated as described in Materials and Methods
in control (CTR, black histograms) and laforin-deﬁcient (Laf-, white histograms) human ﬁbroblasts (A) and in MEFs from control (Epm2a
+/+, black histograms)
and laforin-deﬁcient (Epm2a
2/2, white histograms) mice (B). Each value represents the mean from three different experiments with duplicated samples, using in
each case two different control cell lines and two different laforin-deﬁcient cells. (C and D) Extracts (75 mg protein) of ﬁbroblasts from a representative control
individual (CTR-1) and from two different LD patients (Laf-1 and Laf-2), incubated for 2 h, without (C) or with (D) the proteasomal inhibitor MG-132 (20 mM)
under conditions which produce high (H, Krebs–Henseleit medium) and low (L, full medium) proteolysis, were analysed on western blots using antibodies that
recognize ubiquitinated proteins and actin, which serves as a loading control. The positions of molecular-mass markers and their size in kDa are indicated on the
left. Upper gels: low exposure (exp.), lower gels: high exposure.
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This was associated with decreased clearance of long-lived
proteins via autophagy and the accumulation of ubiquitinated
proteins and the endogenous autophagy substrate, p62. The
impaired autophagy associated with the lack of laforin corre-
lated with increased activity of the autophagy inhibitor
mTOR. In agreement with these observations, it has been
recently shown that laforin-deﬁcient mice have higher levels
of the autophagy substrate tau (33) in their brains (34). Con-
sistent with these data, we found that laforin overexpression
induced autophagy and enhanced autophagy substrate clear-
ance only in autophagy-competent cells. This was assessed
by measuring the formation of autophagosomes by LC3-II
western blotting, by immunoﬂuorescence quantiﬁcation of
EGFP-LC3 vesicles (autophagosomes) and by assessing the
accumulation of mutant huntingtin exon 1, an autophagy sub-
strate, in wild-type and autophagy-incompetent (atg5
2/2)
cells. Thus, the ability of laforin to stimulate autophagy is
not saturated in cells.
Theaccumulationofubiquitinatedproteinsisawell-described
phenomenonthatoccursinautophagy-compromisedtissues(25).
This may occur if some proteins are speciﬁcally targeted to
autophagy via ubiquitination and subsequent binding to adaptor
proteins that link to the autophagic machinery (35,36).
However, another reason for the accumulation of ubiquitinated
proteinsmaybebecauseautophagyinhibitionresultsinasecond-
ary reduction in ﬂux through the ubiquitin-proteasome system.
This phenomenon is driven by the accumulation of p62, which
appearstoimpairthedeliveryofubiquitinatedproteinstothepro-
teasome (37). Thus, it is possible that the reduced rates of auto-
phagy in LD may have effects on the other major intracellular
proteolytic system, the ubiquitin proteasome pathway.
The effects of laforin on autophagy are mTOR-dependent,
as no effects are seen in tsc2
2/2 cells, and it is well known
Figure 3. Loss of laforin slows macroautophagy in vivo.( A and B) Representative immunoblots using anti-LC3 or anti-actin of mouse liver lysates (100 mg
protein) from control (Epm2a
+/+) and laforin-deﬁcient (Epm2a
2/2) mice, 3 months (A) and 1 year (B) old, starved for 24 h and injected (+) or not (2)
with 2 mg/100 g weight leupeptin. The positions of LC3-I and LC3-II bands are indicated. (C) Mouse liver lysates (50 mg protein) of 1-month and 3-month-old
mice, starved for 24 h (high proteolysis) or fed (0, low proteolysis), were immunoblotted with p62 and actin antibodies. (D) The bands from four independent
experiments (two from each 1-month and 3-month-old mice) similar to those shown in (C) were assessed by densitometry and normalized to the corresponding
actin bands. (E and F) Control (Epm2a
+/+) and laforin-deﬁcient (Epm2a
2/2) mice, 1 (E) and 3 (F) months old, were fed ad libitum (0) or fasted (starvation) for
12 or 24 h. Mouse liver lysates (100 mg protein) were analysed on western blots using antibodies that recognize ubiquitinated proteins and actin, which serves as
a loading control. The positions of molecular-mass markers and their size in kDa are indicated on the left.
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suggested that laforin dephosphorylates GSK3-b at Ser 9,
thereby activating this enzyme (38). Lafora bodies are
poorly branched polyglucosans, which could arise from an
excess of glycogen synthase activity relative to glycogen
branching enzyme activity. Glycogen synthase kinase 3
(GSK3) is the principal inhibitor of glycogen synthase.
Thus, if laforin were a key GSK3 phosphatase, then one
would expect that the loss of activity of this phosphatase
would decrease GSK3 activity, increase glycogen synthase
activity and thereby increase the formation of Lafora bodies.
Unfortunately, this model is not supported by all studies,
including analyses of Laforin null mice (34).
The exact mechanism for the laforin effect on autophagy is
still elusive and may remain so for some time pending identi-
ﬁcation of authentic substrates. It is quite possible that laforin
may have many substrates (such as other phosphatases), par-
ticularly since it is a dual speciﬁcity phosphatase that can
hydrolyze phosphotyrosine as well as phosphoserine/threonine
substrates in vitro (reviewed in 16). Thus the identiﬁcation of
the speciﬁc substrates relevant to autophagy will be the chal-
lenge. However, the consequences of its lack of activity in LD
patients are easier to predict. Previous analyses of mice that
lack laforin revealed progressive changes in the properties
and structure of glycogen that paralleled the formation of
Lafora bodies. One of the features observed was a progressive
accumulation of glycogen, which also became more phos-
phorylated and insoluble (18). Since Lafora bodies are com-
posed of poorly branched, water-insoluble, glycogen-like
polymers that are also decorated with antiubiquitin antibodies,
we believe that it is likely that decreased autophagy caused by
laforin deﬁciency will enhance their accumulation, given that
autophagy compromise leads to the accumulation of glycogen,
ubiquitinated proteins and aggregate-prone proteins (27,39)
(Fig. 7). Indeed, it appears that glycogen autophagy is regu-
lated via the mTOR signalling pathway, which is perturbed
by the loss of laforin activity. In addition to enhancing for-
mation of Lafora bodies, which may be a toxic entity in LD,
autophagy deﬁciency also increases cellular susceptibility to
various toxic insults, which may further exacerbate the
problem (40).
The situation we have described has similarities and differ-
ences when compared with lysosomal storage diseases associ-
ated with hydrolase deﬁciencies. Both sets of conditions
exhibit impaired autophagic ﬂux and the accumulation of
various substrates in the affected tissues. However, there are
important differences. In lysosomal storage diseases, auto-
phagy is impaired not by reduced autophagosome synthesis,
as occurs in laforin deﬁciency, but due to a partial block in
the delivery of autophagosomes to lysosomes (22). Indeed,
lysosomal storage diseases are frequently characterized by
the accumulation of autophagosomes (22). Also, in lysosomal
storage diseases, it is likely that there is an initial loss of lyso-
somal enzyme function that then leads to impaired autophagic
ﬂux, while in laforin deﬁciency the impaired autophagic ﬂux
may be a direct consequence of enzyme activity, since we
saw increased autophagy with laforin overexpression. Cur-
rently, we do not know how early the autophagy defect is in
the pathogenic cascade of LD. While it is likely that the
Lafora bodies contribute to pathology, our data do raise the
possibility that autophagy compromise may be an important
driver of pathology in its own right (independent of the
Lafora bodies), but also that the formation of these inclusions
may be enhanced as a consequence of impaired clearance.
MATERIALS AND METHODS
Plasmids
EGFP-HDQ74 construct was described previously (41). Con-
structs received as kind gifts were EGFP-LC3 (42) and
Myc-Laforin (43).
Mammalian cell culture and transfection
Human ﬁbroblasts were obtained from two patients with two
different mutations (Y86X (Laf-1) and R241X (Laf-2)) in
the laforin gene and with the clinical features of LD.
Control ﬁbroblasts were obtained from healthy subjects
matched by sex and age. Cells were cultured at 378Ci na
humidiﬁed 5% CO2 atmosphere in MEM supplemented with
15% foetal bovine serum, 1% MEM amino acids, 0.5%
MEM non-essential amino acids, 1% glutamine, 1% vitamins,
100 units/ml penicillin and 100 mg/ml streptomycin (all from
Invitrogen Life Technologies). For starvation conditions
(high proteolysis medium, H), cells were switched, after
washing, from full growth medium (low proteolysis medium, L)
to Krebs–Henseleit medium (118.4 mM NaCl, 4.75 mM KCl,
1.19 mM KH2PO4, 2.54 mM MgSO4, 2.44 mM CaCl2.2H2O,
Figure 4. mTOR signalling pathway is upregulated in laforin-deﬁcient cells.
(A) Human ﬁbroblasts from two control individuals (CTR-1 and CTR-2)
and from two different LD patients (Laf-1 and Laf-2) were incubated for
2 h under conditions of high (H, Krebs–Henseleit medium) and low (L, full
medium) proteolysis in the cells. Then, extracts (75 mg) were prepared to
determine the activation state of the down-stream target of mTOR p70S6
kinase (S6K) by immunoblot analysis, using antibodies which recognize phos-
phorylated Thr
389 in p70S6 kinase (P-S6K) and total S6K. (B) mTOR acti-
vation was also analysed by the same procedures in liver extracts from
3-month-old control (Epm2a
+/+) and laforin-deﬁcient (Epm2a
2/2) mice,
starved for 24 h (high proteolysis conditions) or fed (0, low proteolysis con-
ditions).
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pH 7.4 and incubated for 2 h at 378C.
COS-7cells,SK-N-SH cells,atg5
+/+ and atg5
2/2 MEFs (44)
and tsc2
+/+ and tsc2
2/2 MEFs (32)w e r em a i n t a i n e di nD M E M
supplemented with 10% foetal bovine serum, 100 units/ml
penicillin/streptomycin and 2 mML -glutamine (all from Sigma-
Aldrich) in 378C, 5% CO2 humidiﬁed incubator. Cells were
transfected with DNA constructs for 4 h using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol.
Laforin-deﬁcient mice
Laforin-deﬁcient Epm2a
2/2 mice (4) were kindly provided by
Dr Antonio V. Delgado-Escueta. Male C57BL/6 wild-type and
isogenic Epm2a
2/2 mice were maintained at the Centro de
Investigaciones Biolo ´gicas (CSIC, Madrid) on a light–dark
12:12 cycle under constant temperature (238C) with free
access to food and water. In some experiments, mice were
treated with leupeptin (0.2 mg/10 g body weight, intraperito-
neally) 1 h before being sacriﬁced. MEFs were isolated from
14-day-old mouse embryos. Epm2a
+/+ and Epm2a
2/2
MEFs were grown in DMEM supplemented with 15% inacti-
vated foetal bovine serum, 1% MEM non-essential amino
acids, 1% glutamine, 1% vitamins, 1% sodium pyruvate,
10
24 M mercaptoethanol, 100 units/ml penicillin and
100 mg/ml streptomycin. One-, 3- and 12-month-old knock-
out, or control mice of the same age were sacriﬁced by cervi-
cal dislocation and livers were dissected for preparation of
tissue extracts.
Western blot
Cell pellets were lysed on ice in Laemmli’s buffer (62.5 mM
Tris–HCl pH 6.8, 2% sodium dodecyl sulphate, 5%
b-mercaptoethanol, 10% glycerol and 0.01% bromophenol
blue) for 30 min in the presence of complete protease inhibitor
cocktail (Roche Diagnostics), boiled for 5–7 min at 1008C
and subjected to western blot analysis, as previously described
(45,46). Mouse monoclonal antibodies which recognize
human laforin have been described previously (12). Other
primary antibodies include anti-LC3 (1:4,000 dilution;
NB100-2220, Novus Biologicals and 1:500 dilution; clone
5F10, Nanotools), anti-p62 (1:1000 dilution; ab-56416,
Abcam), anti-ubiquitinated proteins (1:5000 dilution;
PW-8805 and PW-8810, BIOMOL), anti-p70S6 kinase
(9202), anti-phospho-p70S6 kinase (Thr389) (9206), anti-S6
ribosomal protein (2217) and anti-phospho-S6 ribosomal
protein (Ser235/236) (2211) (all 1:1000 dilutions from Cell
Signalling Technology), anti-Myc (1:3000 dilution;
11667203001, Roche Diagnostics), anti-tubulin (1:4,000
dilution; T-6199) and anti-actin (1:5000 dilution; A-2066)
(Sigma-Aldrich). Blots were probed with anti-mouse or anti-
rabbit IgG-HRP secondary antibody (1:4000 dilutions) and
visualized using ECL detection kit (GE Healthcare).
Phospho-speciﬁc antibodies were always used in the ﬁrst
round of immunoblotting. After treating the membrane with
stripping buffer (0.1 M glycine, pH 2.3), it was probed using
the antibodies that recognize the total amount of the speciﬁc
protein of interest.
Figure 5. Wild-type laforin induces autophagy and facilitates the clearance of autophagy substrates. (A) COS-7 or SK-N-SH cells, transfected with 2 mg
pcDNA3.1 (empty vector) or Myc-Laforin for 4 h, were treated with or without 400 nM baﬁlomycin A1 in the last 4 h of the 24 h post-transfection period. Over-
expression of wild-type laforin increased autophagosome synthesis, as analysed by immunoblotting with anti-LC3 antibody (upper gels: low exposure (exp.),
lower gels: high exposure) and densitometric analysis of LC3-II levels relative to tubulin. (B) COS-7 cells, transfected with 0.5 mg EGFP-LC3 and either
1.5 mg pcDNA3.1 (empty vector) or Myc-Laforin for 4 h, were ﬁxed and analysed for EGFP-LC3 vesicles at 24 h post-transfection. Overexpression of wild-type
laforin increased the proportion of transfected (EGFP-positive) cells with EGFP-LC3 vesicles. (C) COS-7 cells, transfected with 0.5 mg EGFP-HDQ74 and either
1.5 mg pcDNA3.1 (empty vector) or Myc-Laforin for 4 h, were ﬁxed and analysed for EGFP-HDQ74 aggregates and cell death at 48 h post-transfection. Over-
expression of wild-type laforin reduced the percentages of tranfected (EGFP-positive) cells with mutant huntingtin aggregates and cell death, assessed by apop-
totic nuclear morphology (see Materials and Methods). (D) atg5
+/+ and atg5
2/2 MEFs, transfected with 0.5 mg EGFP-HDQ74 and either 1.5 mg pcDNA3.1
(empty vector) or Myc-Laforin for 4 h, were ﬁxed and analysed for EGFP-HDQ74 aggregates at 48 h post-transfection. Overexpression of wild-type laforin
reduced mutant huntingtin aggregates in atg5
+/+ MEFs, but not in atg5
2/2 MEFs. atg5
2/2 MEFs had increased aggregates compared with atg5
+/+ MEFs.
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Pulse-chase experiments and inhibition of autophagy.H u m a n
control and LD patient ﬁbroblasts or Epm2a
+/+ and
Epm2a
2/2 MEFs were incubated for 48 h in fresh full
medium with 2 mCi/ml [
3H]valine (Hartmann Analytic
Gmbh), followed by a 24 h chase in fresh full medium contain-
ing 10 mM L-valine to degrade short-lived proteins (47). Then,
all cultures were incubated for 4 h under high proteolysis con-
ditions in Krebs–Henseleit medium with 10 mM Hepes, pH
7.4, containing 10 mM valine and the indicated additions.
Protein degradation, which was analysed 1 h later to ensure
maximal effects of the various additions and for only 3 h to
avoid possible secondary effects, was calculated at intervals
of 1.5 h by measuring the net release of trichloroacetic acid-
soluble radioactivity from the labelled cells into the culture
medium and expressed as percentage of protein degraded in
1 h. The contribution of macroautophagy was calculated
using 10 mM 3-methyladenine (Sigma-Aldrich) as previously
described (47).
Assessment of autophagic ﬂux by LC3-II levels with baﬁlomy-
cin A1. Endogenous LC3-II levels, which directly correlate
with autophagosome numbers (42), were detected with
anti-LC3 antibody and densitometric analysis relative to
actin. To assess autophagic ﬂux, LC3-II was measured in the
presence of 400 nM baﬁlomycin A1 (treated in the last 4 h),
which clamped LC3-II/autophagosome degradation (48).
This assay has been established previously with various auto-
phagy modulators (46,49–51).
Assessment of autophagy by EGFP-LC3 vesicles. The percen-
tage of EGFP-positive cells with .5 EGFP-LC3 vesicles were
assessed with a ﬂuorescence microscope, as previously
described (50). Alternatively, the number of ﬂuorescent dots
per cell was counted.
Quantiﬁcation of mutant huntingtin aggregates and cell
death
The percentage of EGFP-positive cells with EGFP-HDQ74
aggregates was assessed with a Nikon Eclipse E600 ﬂuor-
escence microscope (plan-apo 60X/1.4 oil immersion lens at
room temperature) (Nikon, Inc.), as previously described
(46,50). Cells were counted as aggregate positive if one or
several aggregates of any size were visible within a cell.
Cell death was assessed as we have done previously
(40,50,51) by determining if there was apoptotic nuclear mor-
phology using DAPI staining and was considered abnormal if
the nucleus was fragmented or condensed to a small size
resulting in a much stronger ﬂuorescence signal compared
with normal nuclei.
Statistical analyses
Densitometric analysis on the immunoblots was done by
Image J software or with an Image Quant ECL (GE
Healthcare), and the P-values were determined by factorial
ANOVA test using STATVIEW v4.53 (Abacus Concepts),
where the control condition was set to 100%. The y-axis
values are shown in percentage (%) and the error bars
denote standard error of mean. The P-values for assessing
EGFP-HDQ74 aggregation or EGFP-LC3 vesicles were
determined by unconditional logistical regression analysis,
using the general log-linear analysis option of SPSS 9
software (SPSS, Chicago), as previously described
(46,50,51). The convention we have used for P values in
all ﬁgures is: ∗∗∗P , 0.001; ∗∗P , 0.01; ∗P , 0.05; NS,
non-signiﬁcant.
Figure 6. Wild-type laforin reduces mTOR activity to regulate autophagy. (A)
COS-7 cells, transfected with 2 mg pcDNA3.1 (empty vector) or Myc-Laforin
for 4 h, were analysed for mTOR activity at 24 h post-transfection by immu-
noblotting with anti-phospho-S6 kinase (P-S6K, Thr389) and anti-phospho-S6
ribosomal protein (P-S6P, Ser235/236) antibodies. Overexpression of wild-
type laforin (detected with anti-myc antibody) reduced phosphorylation of
S6K and S6P relative to the total proteins. (B) tsc2
+/+ and tsc2
2/2 MEFs,
transfected with 0.5 mg EGFP-LC3 and either 1.5 mg pcDNA3.1 (empty
vector) or Myc-Laforin for 4 h, were ﬁxed and analysed for EGFP-LC3 ves-
icles at 24 h post-transfection. Overexpression of wild-type laforin increased
the proportion of cells with EGFP-LC3 vesicles in tsc2
+/+ MEFs, but not
in tsc2
2/2 MEFs. tsc2
2/2 MEFs had a lower proportion of cells with
EGFP-LC3 vesicles compared with tsc2
+/+ MEFs. (C) tsc2
+/+ and tsc2
2/2
MEFs, transfected with 0.5 mg EGFP-HDQ74 and either 1.5 mg pcDNA3.1
(empty vector) or Myc-Laforin for 4 h, were ﬁxed and analysed for
EGFP-HDQ74 aggregates at 48 h post-transfection. Overexpression of wild-
type laforin reduced mutant huntingtin aggregates in tsc2
+/+ MEFs, but not
in tsc2
2/2 MEFs. tsc2
2/2 MEFs had increased aggregates compared with
tsc2
+/+ MEFs.
Figure 7. Schematic representation of regulation of autophagy by laforin and
the disease consequences. Wild-type laforin induces autophagy by inhibiting
mTOR in a TSC2-dependent manner. Loss of laforin in LD activates mTOR
and inhibits autophagy. An impairment of autophagy in LD may contribute
to the disease pathogenesis (indicated in dashed line).
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